A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222.
Halle C F MooreWilliam E BarlowGeorge SomloJulie R GralowAnne F SchottDaniel F HayesPeter KuhnJames B HicksLisa WelterPhilip A DyChristina H YeonAlison K ConlinErnie BalcuevaDanika L LewDebasish TripathyLajos PusztaiGabriel N HortobagyiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Although power of the study was limited, the findings were unable to support the routine use of everolimus combination endocrine therapy in the first-line treatment of advanced hormone-sensitive breast cancer. Prognostic impact of baseline ctDNA and copy number variations in CTC was demonstrated.